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Siu-Tim Cheung4, Ka-Fai To2,3 and Kwok-Wai Lo2,3*Abstract
Background: Nasopharyngeal carcinoma is a distinct type of head and neck cancer which is consistently associated
with Epstein-Barr virus (EBV). The C666-1 cell line is the only in vitro native EBV-infected NPC cell model commonly
used for study of the viral-host interaction. Nevertheless, the complete EBV genome sequence in this in vitro
EBV-infected NPC model has not been characterized.
Objective: To determine the complete EBV genome sequence in C666-1 cells.
Methods: The C666-1 genome was sequenced by 100-bases pair-end massive parallel sequencing. Bioinformatics
analysis was performed to extract the EBV sequences and construct an EBV consensus sequence map. PCR
amplification and Sanger DNA sequencing were used for sequence validation and gap filling. A phylogenetic
analysis of EBV strain in C666-1 cells and other reported EBV strains was performed.
Results: A 171,317 bp complete EBV genome of C666-1 was successfully constructed (GenBank accession number:
KC617875). Phylogenetic analysis of EBV genome in C666-1 revealed that the C666-1 EBV strain is closely related to
the reported strains in NPC primary tumors.
Conclusion: C666-1 contains a representative NPC-associated EBV genome and might serve as an important model
for studying the roles or function of viral proteins in NPC tumorigenesis.
Keywords: Epstein-Barr virus, Nasopharyngeal carcinoma, Whole-genome deep sequencing, Single-nucleotide
variations, Indels, Phylogenetic analysis, BNRFFindings
NPC is a distinct type of head and neck cancer which is
consistently associated with Epstein-Barr virus (EBV).
Detection of clonal EBV genome in both precancerous
lesions and invasive cancers indicates that EBV latent in-
fection is an early event in the tumorigenesis of NPC.
Since we established the EBV-positive NPC cell line
C666-1 and reported it about fifteen years ago, it has
been widely used for investigating host-viral interaction,
elucidating the function and transcriptional regulation of
EBV-encoded latent genes and miRNAs, and developing* Correspondence: kwlo@cuhk.edu.hk
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provided the original work is properly cited.EBV targeting therapeutic strategies [1]. The origin of
this cell line was from an undifferentiated NPC biopsy of
a Hong Kong patient [1]. It contains normal episomal
EBV genome and shows latency II EBV gene expression
pattern. A number of studies demonstrated the distinct
NF-κb, STAT3, AKT and NOTCH pathways in this cell
line as well as the in vivo samples including EBV-
positive NPC xenografts (e.g., C15, C17, xeno-2117) and
primary tumors [2]. Recently, two novel EBV-encoded
microRNAs, miR-BART21 and miR-BART22 have been
discovered from this EBV-positive epithelial cell line [3].
Despite C666-1 being the only in vitro native EBV-
infected NPC model worldwide, the EBV genome in this
cell line has not been fully characterized until now. To fa-
cilitate the EBV-related studies using this unique cell line,
we constructed the EBV genome map through bioin-
formatic analysis and experimental validation of our re-
cent whole-genome deep sequencing results (Additionale distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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genomic sequencing on Illumina HiSeq 2000 genome se-
quencer, the C666-1 genome was sequenced with average >
75-fold coverage as described [4]. A total of 2,511,210,660
reads (251 Gb) were collected from the sample. By using an
approach that combines the results of two alignment strat-
egies, namely aligning the reads to both human and EBV
reference genomes (EBV-WT; GeneBank accession number
AJ507799) at the same time, and aligning them first to theFigure 1 Characterization of the EBV genome sequence derived from
Circos plot demonstrates the genome-wide comparison of SNVs and indels
strains (HKNPC1, red bars; GD2, orange bars; GD1, blue bars; AG876, grey b
Summary of SNVs and indels identified in C666-1 strain. (c) Phylogenetic an
GD1, GD2, AG876 and EBV-WT. (d) A nonsense mutation in codon 333 (Q t
sequence from the NPC xenograft xeno-2117 is also shown.human genome and then the remaining reads to the EBV
reference genome, we extracted a total of 857,595 kb EBV
sequences from the collected C666-1 data. A high coverage
value of 504 folds to EBV genome was yielded. All uniquely
mapped EBV sequences were assembled into a 143,734 bp
consensus sequence with a read depth of at least 10 reads.
We validated the poorly aligned and questionable regions
and filled up the gaps by PCR amplification and con-
ventional Sanger DNA sequencing. The regions failed to bewhole-genome deep sequencing of NPC cell line C666-1. (a)
in EBV genome of C666-1 (green bars) and those of other reported
ars). The WT-EBV genome sequence was used as reference. (b)
alysis of the genome sequences in five EBV strains, C666-1, HKNPC1,
o stop) of BNRF1 identified in the C666-1 strain. The wild type
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sented by tracts of Ns as described previously [5]. A
171,317 bp complete EBV genome of C666-1 was cons-
tructed (Figure 1a). This newly assembled C666-1 EBV se-
quence was submitted to GenBank with accession number
KC617875. The study was approved by the University Ani-
mal Experimentation Ethics Committee (AEEC) (13-036-
MIS) of the Chinese University of Hong Kong.
In this study, we have assembled the EBV genome in
C666-1 using high-coverage genome sequencing data.
Since no PCR amplification was involved, both homo-
genous and heterogeneous genome variations are accur-
ately determined. Comparing with the EBV-WT reference
genomic sequence (AJ507799), we have revealed a total of
1,268 homogenous and 87 heterogeneous sequence varia-
tions. These changes include 127 indels and 1,228 SNVs.
Among the SNVs, 907 are located within the coding re-
gions and 41.3% (386/907) of them are nonsynonymous
(Figure 1b). The sequence variations in selected SNVs were
confirmed by Sanger DNA sequencing. Phylogenetic
analysis of whole EBV genomes in C666-1 and the reported
strains (EBV-WT, AG876, GD1, GD2, and HKNPC1)
showed that C666-1 is closely related to the GD2 and
HKNPC1 strains (Figure 1c) [5,6]. It has great divergenceEBNA1
LMP2A
BZLF1
Figure 2 Phylogenetic analysis of EBNA1, LMP1, LMP2A, LMP2B, BZLF
EBV strains (HKNPC1, GD1, GD2, AG876 and WT-EBV).with the AG876 and reference EBV-WT genome. Similar
results were observed when we compared the protein se-
quences of various EBV lytic (BZLF1, BLLF1) and latent
(EBNA1, LMP1, LMP2) genes (Figure 2). A number of
studies have also shown that BZLF1 and LMP1 sequences
of the isolates from Hong Kong NPC patients are distinct
from that of the EBV-infected lymphoid cells derived in Af-
rica or Western countries [7–9]. The findings imply that
C666-1 might serve as an important model for studying the
roles or functions of viral proteins in NPC tumorigenesis.
Among the four EBV strains from South China, the isolate
from NPC patient’s saliva (GD1) shows the greatest
divergence with those from the tumors (C666-1, GD2,
HKNPC1). This finding suggests the presence of tumor-
associated EBV strain(s) in NPC patients. Nevertheless, a
comprehensive sequencing of EBV isolates from saliva,
peripheral blood and tumor specimens in a panel of NPC
patients may prove this hypothesis. A summary of non-
synonymous SNVs in the majority of EBV-encoded lytic
and latent genes of C666-1 strain versus those of GD2 and
HKNPC1 is shown in Additional file 2: Table S1. In the
latent genes including EBNA1, EBNA3B/3C, LMP1 and
LMP2B genes, high frequencies of C666-1 specific non-
synonymous SNVs were observed. The prevalence andLMP1
BLLF1
LMP2B
1 and BLLF1 protein sequences of C666-1 and other reported
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Previously, we have demonstrated that multiple EBV-
encoded BART miRNAs (miR-BART1-5p, miR-BART16
and miR-BART17-5p) target the 3′UTR of the LMP1 gene
[10]. The predicted target sequences of these 3 EBV-
encoded BART miRNAs in the 3′UTR of the LMP1 gene
are highly conserved in the NPC-derived EBV strains. In
this study, we also found no polymorphism in the predicted
target sequences of the miR-BART1-5p, 16, and 17-5p in
the C666-1 EBV strain.
Apart from the missense mutations, a homogenous
nonsense mutation in the lytic gene, BNRF1, which en-
codes an EBV major tegument protein was found. We
confirmed the mutation in C666-1 by PCR amplification
and Sanger Sequencing (Figure 1d). This finding indi-
cates the deficiency of BNRF1 protein expression in this
in vitro EBV-positive NPC models. Notably, it was
reported that EBV with BNRF1 deletion also showed ef-
ficient lytic replication and production of mature viral
particles. There are no major structural alterations in
the BNRF1-deleted virus [11]. Further elucidation of the
virus production and lytic cycle of this BNRF1-deficient
C666-1 strain is needed. On the other hand, a recent
study has reported that BNRF1 activates viral early gene
BZLF1 transcription via disrupting cellular DAXX-
ATRX in 293 cells. Thus, BNRF1 deficiency may help to
maintain the latent EBV genome in NPC cells [12]. On
the other hand, loss of BNRF1 in the C666-1 strain may
impact the escape from the host immune responses in
the NPC patients since BNRF1 is a defined target of the
EBV-specific T-helper-cell response.
In summary, we delineated the whole EBV genome se-
quence in C666-1, which might serve as an important
resource for NPC studies. The phylogenetic analysis in-
dicates the C666-1 strain as a representative strain for
EBV-associated NPC.
Additional files:
Additional file 1: Supplementary methodology.
Additional file 2: Table S1. Non-synonymous mutations and amino
acid changes commonly found in NPC tumor samples (C666-1, HKNPC1
and GD2).
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